

ACROLEIN, CROTONALDEHYDE, AND ARECOLINE

VOLUME 128

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 29 October–13 November 2020

LYON, FRANCE - 2021

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	7
A. GENERAL PRINCIPLES AND PROCEDURES	7
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review	9
4. The Working Group and other meeting participants.....	9
5. Working procedures.....	11
6. Overview of the scientific review and evaluation process	12
7. Responsibilities of the Working Group.....	14
B. SCIENTIFIC REVIEW AND EVALUATION	15
1. Exposure characterization	15
2. Studies of cancer in humans.....	18
3. Studies of cancer in experimental animals.....	23
4. Mechanistic evidence	26
5. Summary of data reported.....	29
6. Evaluation and rationale.....	30
References.....	35
GENERAL REMARKS	39
ACROLEIN	45
1. Exposure Characterization	45
1.1 Identification of the agent	45
1.2 Production and use.....	46
1.3 Methods of detection and quantification.....	47
1.4 Occurrence and exposure.....	49
1.5 Regulations and guidelines	66
1.6 Quality of exposure assessment in key epidemiological studies	67

2. Cancer in Humans	72
2.1 Descriptions of individual studies.....	72
2.2 Evidence synthesis for cancer in humans.....	83
3. Cancer in Experimental Animals	84
3.1 Mouse	84
3.2 Rat	99
3.3 Hamster	102
3.4 Evidence synthesis for cancer in experimental animals	103
4. Mechanistic Evidence.....	104
4.1 Absorption, distribution, metabolism, and excretion.....	104
4.2 Evidence relevant to key characteristics of carcinogens.....	108
4.3 Data relevant to comparisons across agents and end-points	154
5. Summary of Data Reported	154
5.1 Exposure characterization.....	154
5.2 Cancer in humans.....	154
5.3 Cancer in experimental animals.....	155
5.4 Mechanistic evidence	155
6. Evaluation and Rationale.....	157
6.1 Cancer in humans.....	157
6.2 Cancer in experimental animals.....	157
6.3 Mechanistic evidence	157
6.4 Overall evaluation	157
6.5 Rationale	157
References.....	158
CROTONALDEHYDE	179
1. Exposure Characterization	179
1.1 Identification of the agent	179
1.2 Production and use	180
1.3 Methods of detection and quantification.....	181
1.4 Occurrence and exposure.....	185
1.5 Regulations and guidelines	198
1.6 Quality of exposure assessment in key epidemiological studies	201
2. Cancer in Humans	202
2.1 Descriptions of individual studies.....	202
2.2 Evidence synthesis for cancer in humans.....	208
3. Cancer in Experimental Animals	209
3.1 Mouse	209
3.2 Rat	214
3.3 Evidence synthesis for cancer in experimental animals	215
4. Mechanistic Evidence.....	216
4.1 Absorption, distribution, metabolism, and excretion.....	216
4.2 Evidence relevant to key characteristics of carcinogens.....	220
4.3 Other relevant evidence	241

5. Summary of Data Reported	242
5.1 Exposure characterization	242
5.2 Cancer in humans	242
5.3 Cancer in experimental animals.....	242
5.4 Mechanistic evidence	243
6. Evaluation and Rationale.....	244
6.1 Cancer in humans	244
6.2 Cancer in experimental animals.....	244
6.3 Mechanistic evidence	244
6.4 Overall evaluation	244
6.5 Rationale	244
References.....	245
ARECOLINE.....	259
1. Exposure Characterization	259
1.1 Identification of the agent	259
1.2 Production and use.....	260
1.3 Methods of detection and quantification.....	261
1.4 Occurrence and exposure	263
1.5 Regulations and guidelines	271
2. Cancer in Humans	272
3. Cancer in Experimental Animals	272
3.1 Mouse.....	272
3.2 Rat	286
3.3 Hamster	287
3.4 Carcinogenicity of metabolites	288
3.5 Evidence synthesis for cancer in experimental animals	289
4. Mechanistic Evidence.....	290
4.1 Absorption, distribution, metabolism, and excretion	290
4.2 Evidence relevant to key characteristics of carcinogens.....	295
4.3 Data relevant to comparisons across agents and end-points	314
5. Summary of Data Reported	315
5.1 Exposure characterization	315
5.2 Cancer in humans	315
5.3 Cancer in experimental animals.....	315
5.4 Mechanistic evidence	316
6. Evaluation and Rationale.....	317
6.1 Cancer in humans	317
6.2 Cancer in experimental animals.....	317
6.3 Mechanistic evidence	317
6.4 Overall evaluation	317
6.5 Rationale	317
References.....	317

LIST OF ABBREVIATIONS	327
ANNEX 1. Supplementary material for acrolein, Section 1, Exposure Characterization	331
ANNEX 2. Supplementary material for crotonaldehyde, Section 1, Exposure Characterization	333
SUMMARY OF FINAL EVALUATIONS	335